Lysosomotropism of Basic Cathepsin K Inhibitors Contributes to Increased Cellular Potencies against Off-Target Cathepsins and Reduced Functional Selectivity (original) (raw)

ArticleOctober 29, 2005

Lysosomotropism of Basic Cathepsin K Inhibitors Contributes to Increased Cellular Potencies against Off-Target Cathepsins and Reduced Functional Selectivity

Click to copy article linkArticle link copied!

Journal of Medicinal Chemistry

Cite this: J. Med. Chem. 2005, 48, 24

Click to copy citationCitation copied!

Published October 29, 2005

research-article

Copyright © 2005 American Chemical Society

Abstract

Click to copy section linkSection link copied!

Abstract Image

The lysosomal cysteine protease cathepsin K is a target for osteoporosis therapy. The aryl-piperazine-containing cathepsin K inhibitor CRA-013783/L-006235 (1) displays greater than 4000-fold selectivity against the lysosomal/endosomal antitargets cathepsin B, L, and S. However, 1 and other aryl-piperazine-containing analogues, including balicatib (10), are ∼10−100-fold more potent in cell-based enzyme occupancy assays than against each purified enzyme. This phenomenon arises from their basic, lipophilic nature, which results in lysosomal trapping. Consistent with its lysosomotropic nature, 1 accumulates in cells and in rat tissues of high lysosome content. In contrast, nonbasic aryl-morpholino-containing analogues do not exhibit lysosomotropic properties. Increased off-target activities of basic cathepsin K inhibitors were observed in a cell-based cathepsin S antigen presentation assay. No potency increases of basic inhibitors in a functional cathepsin K bone resorption whole cell assay were detected. Therefore, basic cathepsin K inhibitors, such as 1, suffer from reduced functional selectivities compared to those predicted using purified enzyme assays.

ACS Publications

Copyright © 2005 American Chemical Society

Cited By

Click to copy section linkSection link copied!

This article is cited by 137 publications.

  1. Yi Zhao, Dennis Y. Liu, Trevor N. Clark, Roger G. Linington, Edward J. Kennelly. Prediction of Bioactive Metabolites from American Aconitum Using Network Integrating Cellular Morphological Profiling and Mass Spectrometry Data. Journal of Natural Products 2025, 88 (7) , 1557-1567. https://doi.org/10.1021/acs.jnatprod.4c01458
  2. Olesja Koleda, Katrina Prane, Edgars Suna. Electrochemical Synthesis of Unnatural Amino Acids via Anodic Decarboxylation of N-Acetylamino Malonic Acid Derivatives. Organic Letters 2023, 25 (44) , 7958-7962. https://doi.org/10.1021/acs.orglett.3c02687
  3. Hong-Rae Kim, Ravichandra Tagirasa, Euna Yoo. Covalent Small Molecule Immunomodulators Targeting the Protease Active Site. Journal of Medicinal Chemistry 2021, 64 (9) , 5291-5322. https://doi.org/10.1021/acs.jmedchem.1c00172
  4. Shikha Kumari, Angelica V. Carmona, Amit K. Tiwari, Paul C. Trippier. Amide Bond Bioisosteres: Strategies, Synthesis, and Successes. Journal of Medicinal Chemistry 2020, 63 (21) , 12290-12358. https://doi.org/10.1021/acs.jmedchem.0c00530
  5. Markus Schade, Beatrix Merla, Bernhard Lesch, Markus Wagener, Simone Timmermanns, Katrien Pletinckx, Torsten Hertrampf. Highly Selective Sub-Nanomolar Cathepsin S Inhibitors by Merging Fragment Binders with Nitrile Inhibitors. Journal of Medicinal Chemistry 2020, 63 (20) , 11801-11808. https://doi.org/10.1021/acs.jmedchem.0c00949
  6. Wenli Ma, Xingxing Ge, Zhishan Xu, Shumiao Zhang, Xiangdong He, JuanJuan Li, Xiaorong Xia, Xiaobing Chen, Zhe Liu. Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes. ACS Omega 2019, 4 (12) , 15240-15248. https://doi.org/10.1021/acsomega.9b01863
  7. Chao Zhao, Dane Huang, Ruyue Li, Yida Xu, Shimin Su, Qiong Gu, Jun Xu. Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach. Journal of Medicinal Chemistry 2019, 62 (12) , 5885-5900. https://doi.org/10.1021/acs.jmedchem.9b00517
  8. Jure Borišek, Matej Vizovišek, Piotr Sosnowski, Boris Turk, Dušan Turk, Barbara Mohar, and Marjana Novič . Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors. Journal of Medicinal Chemistry 2015, 58 (17) , 6928-6937. https://doi.org/10.1021/acs.jmedchem.5b00746
  9. Allen A. Thomas, Kevin W. Hunt, Brad Newhouse, Ryan J. Watts, Xingrong Liu, Guy Vigers, Darin Smith, Susan P. Rhodes, Karin D. Brown, Jennifer N. Otten, Michael Burkard, April A. Cox, Mary K. Geck Do, Darrin Dutcher, Sumeet Rana, Robert K. DeLisle, Kelly Regal, Albion D. Wright, Robert Groneberg, Jiangpeng Liao, Kimberly Scearce-Levie, Michael Siu, Hans E. Purkey, and Joseph P. Lyssikatos . 8-Tetrahydropyran-2-yl Chromans: Highly Selective Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors. Journal of Medicinal Chemistry 2014, 57 (23) , 10112-10129. https://doi.org/10.1021/jm5015132
  10. Janina Schmitz, Anna-Madeleine Beckmann, Adela Dudic, Tianwei Li, Robert Sellier, Ulrike Bartz, and Michael Gütschow . 3-Cyano-3-aza-β-amino Acid Derivatives as Inhibitors of Human Cysteine Cathepsins. ACS Medicinal Chemistry Letters 2014, 5 (10) , 1076-1081. https://doi.org/10.1021/ml500238q
  11. Roberta Ettari, Lucia Tamborini, Ilenia C. Angelo, Nicola Micale, Andrea Pinto, Carlo De Micheli, and Paola Conti . Inhibition of Rhodesain as a Novel Therapeutic Modality for Human African Trypanosomiasis. Journal of Medicinal Chemistry 2013, 56 (14) , 5637-5658. https://doi.org/10.1021/jm301424d
  12. Kevin W. Hunt, Adam W. Cook, Ryan J. Watts, Christopher T. Clark, Guy Vigers, Darin Smith, Andrew T. Metcalf, Indrani W. Gunawardana, Michael Burkard, April A. Cox, Mary K. Geck Do, Darrin Dutcher, Allen A. Thomas, Sumeet Rana, Nicholas C. Kallan, Robert K. DeLisle, James P. Rizzi, Kelly Regal, Douglas Sammond, Robert Groneberg, Michael Siu, Hans Purkey, Joseph P. Lyssikatos, Allison Marlow, Xingrong Liu, and Tony P. Tang . Spirocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: From Hit to Lowering of Cerebrospinal Fluid (CSF) Amyloid β in a Higher Species. Journal of Medicinal Chemistry 2013, 56 (8) , 3379-3403. https://doi.org/10.1021/jm4002154
  13. James J. Crawford, Peter W. Kenny, Jonathan Bowyer, Calum R. Cook, Jonathan E. Finlayson, Christine Heyes, Adrian J. Highton, Julian A. Hudson, Anja Jestel, Stephan Krapp, Scott Martin, Philip A. MacFaul, Benjamin P. McDermott, Thomas M. McGuire, Andrew D. Morley, Jeffrey J. Morris, Ken M. Page, Lyn Rosenbrier Ribeiro, Helen Sawney, Stefan Steinbacher, Caroline Smith, and Alexander G. Dossetter . Pharmacokinetic Benefits of 3,4-Dimethoxy Substitution of a Phenyl Ring and Design of Isosteres Yielding Orally Available Cathepsin K Inhibitors. Journal of Medicinal Chemistry 2012, 55 (20) , 8827-8837. https://doi.org/10.1021/jm301119s
  14. Alexander G. Dossetter, Howard Beeley, Jonathan Bowyer, Calum R. Cook, James J. Crawford, Jonathan E. Finlayson, Nicola M. Heron, Christine Heyes, Adrian J. Highton, Julian A. Hudson, Anja Jestel, Peter W. Kenny, Stephan Krapp, Scott Martin, Philip A. MacFaul, Thomas M. McGuire, Pablo Morentin Gutierrez, Andrew D. Morley, Jeffrey J. Morris, Ken M. Page, Lyn Rosenbrier Ribeiro, Helen Sawney, Stefan Steinbacher, Caroline Smith, and Madeleine Vickers . (1R,2R)-N-(1-Cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): A Potent and Highly Selective Cathepsin K Inhibitor for the Treatment of Osteoarthritis. Journal of Medicinal Chemistry 2012, 55 (14) , 6363-6374. https://doi.org/10.1021/jm3007257
  15. Nan Zheng, Hobart Ng Tsai, Xinyuan Zhang, and Gus R. Rosania . The Subcellular Distribution of Small Molecules: From Pharmacokinetics to Synthetic Biology. Molecular Pharmaceutics 2011, 8 (5) , 1619-1628. https://doi.org/10.1021/mp200092v
  16. Jose M. Coterón, David Catterick, Julia Castro, María J. Chaparro, Beatriz Díaz, Esther Fernández, Santiago Ferrer, Francisco J. Gamo, Mariola Gordo, Jiri Gut, Laura de las Heras, Jennifer Legac, Maria Marco, Juan Miguel, Vicente Muñoz, Esther Porras, Juan C. de la Rosa, Jose R. Ruiz, Elena Sandoval, Pilar Ventosa, Philip J. Rosenthal and Jose M. Fiandor . Falcipain Inhibitors: Optimization Studies of the 2-Pyrimidinecarbonitrile Lead Series. Journal of Medicinal Chemistry 2010, 53 (16) , 6129-6152. https://doi.org/10.1021/jm100556b
  17. John G. Allen, Christopher Fotsch and Philip Babij . Emerging Targets in Osteoporosis Disease Modification. Journal of Medicinal Chemistry 2010, 53 (11) , 4332-4353. https://doi.org/10.1021/jm9018756
  18. Anthony E. Klon and, David J. Diller. Library Fingerprints: A Novel Approach to the Screening of Virtual Libraries. Journal of Chemical Information and Modeling 2007, 47 (4) , 1354-1365. https://doi.org/10.1021/ci7000204
  19. Jusuk Lee, Go-Ni Jung, Kyung Jin Jung, Jun Woo Kim, Min-Jung Ma, Yuri Lee, Ji Hoon Yu, Sang-Hyun Min, Ji Hoon Lee. Pyrrolopyrimidines: A promising scaffold for the development of novel cathepsin K inhibitors. European Journal of Medicinal Chemistry 2026, 302 , 118323. https://doi.org/10.1016/j.ejmech.2025.118323
  20. Xuan Guan, Shu Cheng, Yifei Yin, Shufang Du. Small-molecule Cathepsin K inhibitors: a medicinal chemistry perspective. Future Medicinal Chemistry 2025, 17 (14) , 1757-1770. https://doi.org/10.1080/17568919.2025.2542717
  21. Durga Geetha, Tom Skaria. Cathepsin S: A key drug target and signalling hub in immune system diseases. International Immunopharmacology 2025, 155 , 114622. https://doi.org/10.1016/j.intimp.2025.114622
  22. Leyre Brizuela, Rene Buchet, Carole Bougault, Saida Mebarek. Cathepsin K Inhibitors as Potential Drugs for the Treatment of Osteoarthritis. International Journal of Molecular Sciences 2025, 26 (7) , 2896. https://doi.org/10.3390/ijms26072896
  23. Araceli Valverde, Anne George, Salvador Nares, Afsar R. Naqvi. Emerging therapeutic strategies targeting bone signaling pathways in periodontitis. Journal of Periodontal Research 2025, 60 (2) , 101-120. https://doi.org/10.1111/jre.13326
  24. Dong Oh Moon. Review of Cathepsin K Inhibitor Development and the Potential Role of Phytochemicals. Molecules 2025, 30 (1) , 91. https://doi.org/10.3390/molecules30010091
  25. P. Smyth, L. Ferguson, J. F. Burrows, R. E. Burden, S. R. Tracey, Ú. M. Herron, M. Kovaleva, R. Williams, A. J. Porter, D. B. Longley, C. J. Barelle, C. J. Scott. Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy. Frontiers in Pharmacology 2023, 14 https://doi.org/10.3389/fphar.2023.1296567
  26. Bridgette Hartley, Wesam Bassiouni, Richard Schulz, Olivier Julien. The roles of intracellular proteolysis in cardiac ischemia–reperfusion injury. Basic Research in Cardiology 2023, 118 (1)https://doi.org/10.1007/s00395-023-01007-z
  27. Viviane Corrêa Santos, Paulo Gaio Leite, Lucianna Helene Santos, Pedro Geraldo Pascutti, Peter Kolb, Fabiana Simão Machado, Rafaela Salgado Ferreira. Structure-based discovery of novel cruzain inhibitors with distinct trypanocidal activity profiles. European Journal of Medicinal Chemistry 2023, 257 , 115498. https://doi.org/10.1016/j.ejmech.2023.115498
  28. Xiaofeng Ding, Chen Zhang, Huajian Chen, Minghua Ren, Xiaodong Liu. Cathepsins Trigger Cell Death and Regulate Radioresistance in Glioblastoma. Cells 2022, 11 (24) , 4108. https://doi.org/10.3390/cells11244108
  29. Paul Richardson. Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. Expert Opinion on Drug Discovery 2021, 16 (11) , 1261-1286. https://doi.org/10.1080/17460441.2021.1933427
  30. Avinash Soundararajan, Sachin Anil Ghag, Sai Supriya Vuda, Ting Wang, Padmanabhan Paranji Pattabiraman. Cathepsin K Regulates Intraocular Pressure by Modulating Extracellular Matrix Remodeling and Actin-Bundling in the Trabecular Meshwork Outflow Pathway. Cells 2021, 10 (11) , 2864. https://doi.org/10.3390/cells10112864
  31. Adam Schafer, Rui Xiong, Laura Cooper, Raghad Nowar, Hyun Lee, Yangfeng Li, Benjamin E. Ramirez, Norton P. Peet, Michael Caffrey, Gregory R. J. Thatcher, Erica Ollmann Saphire, Han Cheng, Lijun Rong, . Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. PLOS Pathogens 2021, 17 (2) , e1009312. https://doi.org/10.1371/journal.ppat.1009312
  32. Markus Blaess, Lars Kaiser, Martin Sauer, René Csuk, Hans-Peter Deigner. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. International Journal of Molecular Sciences 2020, 21 (14) , 4953. https://doi.org/10.3390/ijms21144953
  33. Voradanu Visetvichaporn, Kyung-Hee Kim, Kyungjin Jung, Yun-Seok Cho, Dae-Duk Kim. Formulation of self-microemulsifying drug delivery system (SMEDDS) by D-optimal mixture design to enhance the oral bioavailability of a new cathepsin K inhibitor (HL235). International Journal of Pharmaceutics 2020, 573 , 118772. https://doi.org/10.1016/j.ijpharm.2019.118772
  34. Fan Du, Lan Bai, Miao He, Wen-Yao Zhang, Yi-Ying Gu, Hui Yin, Yun-Jun Liu. Design, synthesis and biological evaluation of iridium(III) complexes as potential antitumor agents. Journal of Inorganic Biochemistry 2019, 201 , 110822. https://doi.org/10.1016/j.jinorgbio.2019.110822
  35. W. Andrew Shockey, Christopher A. Kieslich, Catera L. Wilder, Valencia Watson, Manu O. Platt. Dynamic Model of Protease State and Inhibitor Trafficking to Predict Protease Activity in Breast Cancer Cells. Cellular and Molecular Bioengineering 2019, 12 (4) , 275-288. https://doi.org/10.1007/s12195-019-00580-5
  36. Keriann M. Backus, Jian Cao, Sean M. Maddox. Opportunities and challenges for the development of covalent chemical immunomodulators. Bioorganic & Medicinal Chemistry 2019, 27 (15) , 3421-3439. https://doi.org/10.1016/j.bmc.2019.05.050
  37. Avick Kumar Ghosh, Indranil Samanta, Anushree Mondal, Wenshe Ray Liu. Covalent Inhibition in Drug Discovery. ChemMedChem 2019, 14 (9) , 889-906. https://doi.org/10.1002/cmdc.201900107
  38. Wenli Ma, Lihua Guo, Zhenzhen Tian, Shumiao Zhang, Xiangdong He, JuanJuan Li, Yuliang Yang, Zhe Liu. Rhodamine-modified fluorescent half-sandwich iridium and ruthenium complexes: potential application as bioimaging and anticancer agents. Dalton Transactions 2019, 48 (15) , 4788-4793. https://doi.org/10.1039/C9DT00999J
  39. Dibyendu Dana, Jeremy Garcia, Ashif I. Bhuiyan, Pratikkumar Rathod, Laura Joo, Daniel A. Novoa, Suneeta Paroly, Karl R. Fath, Emmanuel J. Chang, Sanjai K. Pathak. Cell penetrable, clickable and tagless activity-based probe of human cathepsin L. Bioorganic Chemistry 2019, 85 , 505-514. https://doi.org/10.1016/j.bioorg.2019.02.032
  40. Si-tu Xue, Ya-li Wang, Xiao-wan Han, Hong Yi, Wei Jiang, Shu-yi Si, Hui-fang Guo, Zhuo-rong Li. Novel cathepsin K inhibitors block osteoclasts in vitro and increase spinal bone density in zebrafish. RSC Advances 2019, 9 (15) , 8600-8607. https://doi.org/10.1039/C8RA10338K
  41. Janina Schmitz, Erik Gilberg, Reik Löser, Jürgen Bajorath, Ulrike Bartz, Michael Gütschow. Cathepsin B: Active site mapping with peptidic substrates and inhibitors. Bioorganic & Medicinal Chemistry 2019, 27 (1) , 1-15. https://doi.org/10.1016/j.bmc.2018.10.017
  42. Erik Lindström, Biljana Rizoska, Ian Henderson, Ylva Terelius, Markus Jerling, Charlotte Edenius, Urszula Grabowska. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. Journal of Translational Medicine 2018, 16 (1)https://doi.org/10.1186/s12967-018-1497-4
  43. Michael R. McClung. Future Therapies. 2018, 603-609. https://doi.org/10.1002/9781119266594.ch80
  44. C. Pitchumani Violet Mary, R. Shankar, S. Vijayakumar. Theoretical studies on the interaction between the nitrile-based inhibitors and the catalytic triad of Cathepsin K. Journal of Biomolecular Structure and Dynamics 2018, 36 (3) , 634-655. https://doi.org/10.1080/07391102.2017.1289863
  45. Jun Lu, Maolin Wang, Ziyue Wang, Zhongqi Fu, Aiping Lu, Ge Zhang. Advances in the discovery of cathepsin K inhibitors on bone resorption. Journal of Enzyme Inhibition and Medicinal Chemistry 2018, 33 (1) , 890-904. https://doi.org/10.1080/14756366.2018.1465417
  46. Sherry Niessen, Melissa M. Dix, Sabrina Barbas, Zachary E. Potter, Shuyan Lu, Oleg Brodsky, Simon Planken, Douglas Behenna, Chau Almaden, Ketan S. Gajiwala, Kevin Ryan, RoseAnn Ferre, Michael R. Lazear, Matthew M. Hayward, John C. Kath, Benjamin F. Cravatt. Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors. Cell Chemical Biology 2017, 24 (11) , 1388-1400.e7. https://doi.org/10.1016/j.chembiol.2017.08.017
  47. Lovro Kramer, Dušan Turk, Boris Turk. The Future of Cysteine Cathepsins in Disease Management. Trends in Pharmacological Sciences 2017, 38 (10) , 873-898. https://doi.org/10.1016/j.tips.2017.06.003
  48. Bin Sun, Jun Liu, Yun Gao, Hong-bo Zheng, Lin Li, Qing-wen Hu, Hui-qing Yuan, Hong-xiang Lou. Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome. European Journal of Medicinal Chemistry 2017, 136 , 603-618. https://doi.org/10.1016/j.ejmech.2017.05.050
  49. Matthew T Drake, Bart L Clarke, Merry Jo Oursler, Sundeep Khosla. Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. Endocrine Reviews 2017, 38 (4) , 325-350. https://doi.org/10.1210/er.2015-1114
  50. Bennett Ma, Bin Luo, Danielle H. Euler, Tara E. Cusick, Gregg Wesolowski, Helmut Glantschnig, Le T. Duong, Yangsi Ou, Steven S. Carroll, Laura S. Lubbers. Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis. Naunyn-Schmiedeberg's Archives of Pharmacology 2017, 390 (4) , 435-441. https://doi.org/10.1007/s00210-017-1356-5
  51. Andrea M. Zuhl, Charles E. Nolan, Michael A. Brodney, Sherry Niessen, Kevin Atchison, Christopher Houle, David A. Karanian, Claude Ambroise, Jeffrey W. Brulet, Elizabeth M. Beck, Shawn D. Doran, Brian T. O’Neill, Christopher W. am Ende, Cheng Chang, Kieran F. Geoghegan, Graham M. West, Joshua C. Judkins, Xinjun Hou, David R. Riddell, Douglas S. Johnson. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors. Nature Communications 2016, 7 (1)https://doi.org/10.1038/ncomms13042
  52. Kakoli Mukherjee, Naibedya Chattopadhyay. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy. Biochemical Pharmacology 2016, 117 , 10-19. https://doi.org/10.1016/j.bcp.2016.04.010
  53. Catera L. Wilder, Charlene Walton, Valencia Watson, Fermin A.A. Stewart, Jade Johnson, Shelly R. Peyton, Christine K. Payne, Valerie Odero-Marah, Manu O. Platt. Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells. The International Journal of Biochemistry & Cell Biology 2016, 79 , 199-208. https://doi.org/10.1016/j.biocel.2016.08.030
  54. Nadia Hamid, Jeffrey P. Krise. The Mechanisms and Therapeutic Consequences of Amine‐Containing Drug Sequestration in Lysosomes. 2016, 423-444. https://doi.org/10.1002/9781118978320.ch18
  55. Shuyan Lu, Bart Jessen, Yvonne Will, Greg Stevens. Lysosome Dysfunction: An Emerging Mechanism of Xenobiotic‐Induced Toxicity. 2016, 445-485. https://doi.org/10.1002/9781118978320.ch19
  56. Mackenzie K. Herroon, Rajgopal Sharma, Erandi Rajagurubandara, Claudia Turro, Jeremy J. Kodanko, Izabela Podgorski. Photoactivated inhibition of cathepsin K in a 3D tumor model. Biological Chemistry 2016, 397 (6) , 571-582. https://doi.org/10.1515/hsz-2015-0274
  57. Jeffrey P. Krise. Intracellular Delivery and Disposition of Small‐Molecular‐Weight Drugs. 2016, 103-130. https://doi.org/10.1002/9781118833322.ch6
  58. Dieter Brömme, Preety Panwar, Serap Turan. Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences. Expert Opinion on Drug Discovery 2016, 11 (5) , 457-472. https://doi.org/10.1517/17460441.2016.1160884
  59. Le T. Duong, Albert T. Leung, Bente Langdahl. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis. Calcified Tissue International 2016, 98 (4) , 381-397. https://doi.org/10.1007/s00223-015-0051-0
  60. Yali Wang, Ruolan Li, Zhihui Zheng, Hong Yi, Zhuorong Li. Identification of novel cathepsin K inhibitors using ligand-based virtual screening and structure-based docking. RSC Advances 2016, 6 (86) , 82961-82968. https://doi.org/10.1039/C6RA14251F
  61. Makoto Tanaka, Yoshitaka Hashimoto, Chihiro Hasegawa. An oral cathepsin K inhibitor ONO-5334 inhibits N- terminal and C- terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women. Bone 2015, 81 , 178-185. https://doi.org/10.1016/j.bone.2015.07.016
  62. Toshiaki Fujii, Mizuho Ishikawa, Akiko Kubo, Yoshitaka Tanaka. Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo. Bone 2015, 81 , 427-434. https://doi.org/10.1016/j.bone.2015.08.016
  63. Urška Verbovšek, Cornelis J.F. Van Noorden, Tamara T. Lah. Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression. Seminars in Cancer Biology 2015, 35 , 71-84. https://doi.org/10.1016/j.semcancer.2015.08.010
  64. R. Jeffrey Neitz, Clifford Bryant, Steven Chen, Jiri Gut, Estefania Hugo Caselli, Servando Ponce, Somenath Chowdhury, Haichao Xu, Michelle R. Arkin, Jonathan A. Ellman, Adam R. Renslo. Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas’ disease. Bioorganic & Medicinal Chemistry Letters 2015, 25 (21) , 4834-4837. https://doi.org/10.1016/j.bmcl.2015.06.066
  65. Polyzois Makras, Sideris Delaroudis, Athanasios D. Anastasilakis. Novel therapies for osteoporosis. Metabolism 2015, 64 (10) , 1199-1214. https://doi.org/10.1016/j.metabol.2015.07.011
  66. Bente L. Langdahl. New treatments of osteoporosis. Osteoporosis and Sarcopenia 2015, 1 (1) , 4-21. https://doi.org/10.1016/j.afos.2015.07.007
  67. Richard D.A. Wilkinson, Rich Williams, Christopher J. Scott, Roberta E. Burden. Cathepsin S: therapeutic, diagnostic, and prognostic potential. Biological Chemistry 2015, 396 (8) , 867-882. https://doi.org/10.1515/hsz-2015-0114
  68. C. Wilczynski, S. Samarasinghe, M. A. Emanuele, N. Emanuele, L. Shah, A. Mazhari. Cathepsins K and S: Role in Bone, Adipocytes, and Glucose Regulation. Clinical Reviews in Bone and Mineral Metabolism 2015, 13 (1) , 2-10. https://doi.org/10.1007/s12018-015-9177-x
  69. H. G. Bone, D. W. Dempster, J. A. Eisman, S. L. Greenspan, M. R. McClung, T. Nakamura, S. Papapoulos, W. J. Shih, A. Rybak-Feiglin, A. C. Santora, N. Verbruggen, A. T. Leung, A. Lombardi. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporosis International 2015, 26 (2) , 699-712. https://doi.org/10.1007/s00198-014-2944-6
  70. Marion Gamsjäger, Heinrich Resch. Cathepsin K-Inhibitoren: präklinische und klinische Daten. Wiener Medizinische Wochenschrift 2015, 165 (3-4) , 65-70. https://doi.org/10.1007/s10354-014-0336-3
  71. Michael R. McClung. Emerging Therapies for Osteoporosis. Endocrinology and Metabolism 2015, 30 (4) , 429. https://doi.org/10.3803/EnM.2015.30.4.429
  72. Sander I van Kasteren, Herman S Overkleeft. Endo-lysosomal proteases in antigen presentation. Current Opinion in Chemical Biology 2014, 23 , 8-15. https://doi.org/10.1016/j.cbpa.2014.08.011
  73. Le T. Duong, Gregg A. Wesolowski, Patrick Leung, Renata Oballa, Maureen Pickarski. Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis. Molecular Cancer Therapeutics 2014, 13 (12) , 2898-2909. https://doi.org/10.1158/1535-7163.MCT-14-0253
  74. Randall Logan, Alex C. Kong, Jeffrey P. Krise. Time‐Dependent Effects of Hydrophobic Amine‐Containing Drugs on Lysosome Structure and Biogenesis in Cultured Human Fibroblasts. Journal of Pharmaceutical Sciences 2014, 103 (10) , 3287-3296. https://doi.org/10.1002/jps.24087
  75. Michael A. Gentile, Do Y. Soung, Carlyle Horrell, Rana Samadfam, Hicham Drissi, Le T. Duong. Increased fracture callus mineralization and strength in cathepsin K knockout mice. Bone 2014, 66 , 72-81. https://doi.org/10.1016/j.bone.2014.04.032
  76. Marko Fonović, Boris Turk. Cysteine cathepsins and extracellular matrix degradation. Biochimica et Biophysica Acta (BBA) - General Subjects 2014, 1840 (8) , 2560-2570. https://doi.org/10.1016/j.bbagen.2014.03.017
  77. Peter A. Lemaire, Lingyi Huang, Ya Zhuo, Jun Lu, Carolyn Bahnck, Shawn J. Stachel, Steve S. Carroll, Le T. Duong. Chondroitin Sulfate Promotes Activation of Cathepsin K. Journal of Biological Chemistry 2014, 289 (31) , 21562-21572. https://doi.org/10.1074/jbc.M114.559898
  78. Jure Borišek, Viktor Drgan, Nikola Minovski, Marjana Novič. Mechanistic interpretation of artificial neural network‐based QSAR model for prediction of cathepsin K inhibition potency. Journal of Chemometrics 2014, 28 (4) , 272-281. https://doi.org/10.1002/cem.2617
  79. Momar Ndao, Christian Beaulieu, W. Cameron Black, Elise Isabel, Fabio Vasquez-Camargo, Milli Nath-Chowdhury, Frédéric Massé, Christophe Mellon, Nathalie Methot, Deborah A. Nicoll-Griffith. Reversible Cysteine Protease Inhibitors Show Promise for a Chagas Disease Cure. Antimicrobial Agents and Chemotherapy 2014, 58 (2) , 1167-1178. https://doi.org/10.1128/AAC.01855-13
  80. Dibyendu Dana, Shatarupa De, Pratikkumar Rathod, Anibal R. Davalos, Daniel A. Novoa, Suneeta Paroly, Viviana M. Torres, Nisar Afzal, Ravi S. Lankalapalli, Susan A. Rotenberg, Emmanuel J. Chang, Gopal Subramaniam, Sanjai Kumar. Development of a highly potent, selective, and cell-active Inhibitor of cysteine cathepsin L–A hybrid design approach. Chemical Communications 2014, 50 (74) , 10875. https://doi.org/10.1039/C4CC04037F
  81. Brenda L Pennypacker, Renata M Oballa, Sonia Levesque, Donald B Kimmel, Le T Duong. Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits. BMC Musculoskeletal Disorders 2013, 14 (1)https://doi.org/10.1186/1471-2474-14-344
  82. Michael R. McClung, Cristiano A. F. Zerbini. Emerging Therapies. 2013, 211-226. https://doi.org/10.1002/9781118316290.ch14
  83. Marko Novinec, Brigita Lenarčič. Cathepsin K: a unique collagenolytic cysteine peptidase. bchm 2013, 394 (9) , 1163-1179. https://doi.org/10.1515/hsz-2013-0134
  84. Cristiano A. F. Zerbini, Michael R. McClung. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. Therapeutic Advances in Musculoskeletal Disease 2013, 5 (4) , 199-209. https://doi.org/10.1177/1759720X13490860
  85. Do Y. Soung, Michael A. Gentile, Le T. Duong, Hicham Drissi. Effects of pharmacological inhibition of cathepsin K on fracture repair in mice. Bone 2013, 55 (1) , 248-255. https://doi.org/10.1016/j.bone.2013.02.010
  86. Ana Torkar, Brigita Lenarčič, Tamara Lah, Vincent Dive, Laurent Devel. Identification of new peptide amides as selective cathepsin L inhibitors: The first step towards selective irreversible inhibitors?. Bioorganic & Medicinal Chemistry Letters 2013, 23 (10) , 2968-2973. https://doi.org/10.1016/j.bmcl.2013.03.041
  87. Pavel K. Mykhailiuk, Viktoriia Starova, Vladimir Iurchenko, Svitlana V. Shishkina, Oleg V. Shishkin, Oleksandr Khilchevskyi, Olga Zaporozhets. 1-Amino-4,4-difluorocyclohexanecarboxylic acid as a promising building block for drug discovery: design, synthesis and characterization. Tetrahedron 2013, 69 (20) , 4066-4075. https://doi.org/10.1016/j.tet.2013.03.072
  88. Donna M. Cartledge, Rita Colella, Lisa Glazewski, Guizhen Lu, Robert W. Mason. Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells. Investigational New Drugs 2013, 31 (1) , 20-29. https://doi.org/10.1007/s10637-012-9826-6
  89. John J.M. Wiener, Alvah Tyson Wickboldt, Steven Nguyen, Siquan Sun, Raymond Rynberg, Michele Rizzolio, Lars Karlsson, James P. Edwards, Cheryl A. Grice. Pyrazole-based arylalkyne Cathepsin S inhibitors. Part III: Modification of P4 region. Bioorganic & Medicinal Chemistry Letters 2013, 23 (4) , 1070-1074. https://doi.org/10.1016/j.bmcl.2012.12.014
  90. Aline Costa, Natalie E. Cusano, Barbara C. Silva, John P. Bilezikian. New Approaches to Osteoporosis Therapeutics. 2013, 1963-1985. https://doi.org/10.1016/B978-0-12-415853-5.00086-8
  91. Jonathan W Choy, Clifford Bryant, Claudia M Calvet, Patricia S Doyle, Shamila S Gunatilleke, Siegfried S F Leung, Kenny K H Ang, Steven Chen, Jiri Gut, Juan A Oses-Prieto, Jonathan B Johnston, Michelle R Arkin, Alma L Burlingame, Jack Taunton, Matthew P Jacobson, James M McKerrow, Larissa M Podust, Adam R Renslo. Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target. Beilstein Journal of Organic Chemistry 2013, 9 , 15-25. https://doi.org/10.3762/bjoc.9.3
  92. Neil Moss, Zhaoming Xiong, Mike Burke, Derek Cogan, Donghong A. Gao, Kathleen Haverty, Alexander Heim-Riether, Eugene R. Hickey, Raj Nagaraja, Matthew Netherton, Kathy O’Shea, Philip Ramsden, Racheline Schwartz, Daw-Tsun Shih, Yancey Ward, Erick Young, Qing Zhang. Exploration of cathepsin S inhibitors characterized by a triazole P1–P2 amide replacement. Bioorganic & Medicinal Chemistry Letters 2012, 22 (23) , 7189-7193. https://doi.org/10.1016/j.bmcl.2012.09.054
  93. Alexander G. Dossetter, Jonathan Bowyer, Calum R. Cook, James J. Crawford, Jonathan E. Finlayson, Nicola M. Heron, Christine Heyes, Adrian J. Highton, Julian A. Hudson, Anja Jestel, Stephan Krapp, Philip A. MacFaul, Thomas M. McGuire, Andrew D. Morley, Jeffrey J. Morris, Ken M. Page, Lyn Rosenbrier Ribeiro, Helen Sawney, Stefan Steinbacher, Caroline Smith. Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition. Bioorganic & Medicinal Chemistry Letters 2012, 22 (17) , 5563-5568. https://doi.org/10.1016/j.bmcl.2012.07.012
  94. Randall Logan, Ryan S Funk, Erick Axcell, Jeffrey P Krise. Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications. Expert Opinion on Drug Metabolism & Toxicology 2012, 8 (8) , 943-958. https://doi.org/10.1517/17425255.2012.691165
  95. Dieter Brömme. Bone Remodeling: Cathepsin K in Collagen Turnover. 2012, 79-97. https://doi.org/10.1002/9783527649327.ch4
  96. Le T Duong. Therapeutic inhibition of cathepsin K—reducing bone resorption while maintaining bone formation. BoneKEy Reports 2012, 1 (5)https://doi.org/10.1038/bonekey.2012.67
  97. Deborah A Nicoll-Griffith. Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease. Expert Opinion on Drug Discovery 2012, 7 (4) , 353-366. https://doi.org/10.1517/17460441.2012.668520
  98. Edgar Deu, Martijn Verdoes, Matthew Bogyo. New approaches for dissecting protease functions to improve probe development and drug discovery. Nature Structural & Molecular Biology 2012, 19 (1) , 9-16. https://doi.org/10.1038/nsmb.2203
  99. Jac Wijkmans, Jan Gossen. Inhibitors of cathepsin K: a patent review (2004 – 2010). Expert Opinion on Therapeutic Patents 2011, 21 (10) , 1611-1629. https://doi.org/10.1517/13543776.2011.616283
  100. Aline G. Costa, Natalie E. Cusano, Barbara C. Silva, Serge Cremers, John P. Bilezikian. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nature Reviews Rheumatology 2011, 7 (8) , 447-456. https://doi.org/10.1038/nrrheum.2011.77

Load all citations

Journal of Medicinal Chemistry

Cite this: J. Med. Chem. 2005, 48, 24

Click to copy citationCitation copied!

Published October 29, 2005

Copyright © 2005 American Chemical Society

Altmetric

-

Citations

Learn about these metrics

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.

Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.

The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated.